Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer

Journal of the Royal Society Interface

Volumn 11, Issue 96, 2014, Pages

  Chen, Chun ^a   Baumann, William T ^a   Xing, Jianhua ^a   Xu, Lingling ^a   Clarke, Robert ^b   Tyson, John J ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast cancer; Endocrine resistance; Intermittent treatment; Potential landscape; Sequential treatment

Indexed keywords

MATHEMATICAL MODELS; TUMORS;

ACQUIRED RESISTANCE; BREAST CANCER; INTERMITTENT TREATMENT; OESTROGEN RECEPTORS; POPULATION-LEVEL MODELS; POTENTIAL LANDSCAPE; SEQUENTIAL TREATMENTS; STATE-TRANSITION MODEL;

DISEASES;

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL MEMBRANE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HYPERSENSITIVITY; MATHEMATICAL MODEL; PHENOTYPE; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENETICS; PATHOLOGY; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MODELS, THEORETICAL; RECEPTORS, ESTROGEN;

EID: 84901447630     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2014.0206     Document Type: Article

References (63)

1. Rimawi MF, Osborne CK. 2012 Breast cancer: blocking both driver and escape pathways improves outcomes. Nat. Rev. Clin. Oncol. 9, 133-134. (doi:10.1038/nrclinonc.2012.9)
2. Musgrove EA, Sutherland RL. 2009 Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643. (doi:10.1038/nrc2713)
3. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F, Group NC-NBC. 2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12, 721-747. (doi:10.1677/erc.1.00857)
4. Clarke R et al. 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22, 7316-7339. (doi:10.1038/sj.onc.1206937)
5. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. 2004 Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer 11, 623-641. (doi:10.1677/erc.1.00778)
6. Ali S, Coombes RC. 2002 Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2, 101-112. (doi:10.1038/nrc721)
7. Stoll BA. 1983 Rechallenging breast-cancer with tamoxifen therapy. Clin. Oncol. 9, 347-351.
8. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI. 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142, 2776-2788. (Pubitemid 32575512)
9. Sabnis G, Goloubeva O, Gilani R, Macedo L, Brodie A. 2010 Sensitivity to the aromatase inhibitor letrozole is prolonged after a 'break' in treatment. Mol. Cancer Therapeutics 9, 46-56. (doi:10.1158/1535-7163.MCT-09-0696)
10. Barrios C et al. 2012 The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann. Oncol. 23, 1378-1386. (doi:10.1093/annonc/mdr593)
11. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W, Berstein L. 2003 Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr. Relat. Cancer 10, 111-130. (doi:10.1677/erc.0.0100111)
12. Santen RJ, Song RX, Zhang ZG, Yue W, Kumar R. 2004 Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin. Cancer Res. 10, 337S-345S. (doi:10.1158/1078- 0432.CCR-031207)
13. Brock A, Chang H, Huang S. 2009 OPINION Nongenetic heterogeneity - a mutation-independent driving force for the somatic evolution of tumours. Nat. Rev. Genet. 10, 336-342. (doi:10.1038/nrg2556)
14. Masamura S, Santner SJ, Heitjan DF, Santen RJ. 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast-cancer cells. J. Clin. Endocr. Metab. 80, 2918-2925.
15. Waddington CH. 1957 The strategy of the genes; a discussion of some aspects of theoretical biology, p. 262. London, UK: Allen & Unwin.
16. Wang J, Zhang K, Xu L, Wang E. 2011 Quantifying the Waddington landscape and biological paths for development and differentiation. Proc. Natl Acad. Sci. USA 108, 8257-8262. (doi:10.1073/pnas.1017017108)
17. Wang J, Xu L, Wang E. 2008 Potential landscape and flux framework of nonequilibrium networks: robustness, dissipation, and coherence of biochemical oscillations. Proc. Natl Acad. Sci. USA 105, 12 271-12 276. (doi:10.1073/pnas. 0800579105)
18. Ao P, Galas D, Hood L, Zhu XM. 2008 Cancer as robust intrinsic state of endogenous molecular - cellular network shaped by evolution. Med. Hypotheses 70, 678-684. (doi:10.1016/j.mehy.2007.03.043)
19. Wang P, Song C, Zhang H, Wu Z, Xing J. 2012 Global epigenetic state network governs cellular pluripotent reprogramming and transdifferentiation. (http://arxiv.org/abs/1209.4603)
20. Zhou JX, Aliyu MDS, Aurell E, Huang S. 2012 Quasi-potential landscape in complex multi-stable systems. J. R. Soc. Interface 9, 3539-3553. (doi:10.1098/rsif.2012.0434)
21. Huang S, Ernberg I, Kauffman S. 2009 Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Sem. Cell Dev. Biol. 20, 869-876. (doi:10.1016/j.semcdb.2009.07.003)
22. Zhu XM, Yin L, Hood L, Ao P. 2004 Robustness, stability and efficiency of phage lambda genetic switch: dynamical structure analysis. J. Bioinform. Comput. Biol. 2, 785-817. (doi:10.1142/S0219720004000946)
23. Zhang L, Radtke K, Zheng LK, Cai AQ, Schilling TF, Nie Q. 2012 Noise drives sharpening of gene expression boundaries in the zebrafish hindbrain. Mol. Syst. Biol. 8, 613. (doi:10.1038/msb.2012.45)
24. Osborne CK, Schiff R. 2011 Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247. (doi:10.1146/annurev-med-070909-182917)
25. Lannigan DA. 2003 Estrogen receptor phosphorylation. Steroids 68, 1-9. (doi:10.1016/S0039-128X(02)00110-1)
26. Zhou W, Slingerland JM. 2014 Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat. Rev. Cancer 14, 26-38. (doi:10.1038/nrc3622)
27. Osborne CK, Shou J, Massarweh S, Schiff R. 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res. 11, 865S-870S. (Pubitemid 40111098)
28. Massarweh S, Schiff R. 2006 Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr. Relat. Cancer 13, S15-S24. (doi:10.1677/erc.1.01273)
29. Bates NP, Hurst HC. 1997 An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 15, 473-481. (doi:10.1038/sj.onc.1201368)
30. Chrysogelos SA, Yarden RI, Lauber AH, Murphy JM. 1994 Mechanisms of EGF receptor regulation in breast-cancer cells. Breast Cancer Res. Treat. 31, 227-236. (doi:10.1007/BF00666156)
31. Rao J, Jiang XM, Wang Y, Chen B. 2011 Advances in the understanding of the structure and function of ER-alpha 36, a novel variant of human estrogen receptor-alpha. J. Steroid Biochem. 127, 231-237. (doi:10.1016/j.jsbmb.2011.08. 004)
32. Zilli M, Grassadonia A, Tinari N, Di Giacobbe A, Gildetti S, Giampietro J, Natoli C, Iacobelli S, Bio-Oncol CIN. 2009 Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim. Biophys. Acta 1795, 62-81. (doi:10.1016/j.bbcan.2008.08.003)
33. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. 2005 The NF kappa B pathway and endocrine-resistant breast cancer. Endocr. Relat. Cancer 12, S37-S46. (doi:10.1677/erc.1.00977)
34. Tyson JJ, Novak B. 2010 Functional motifs in biochemical reaction networks. Annu. Rev. Phys. Chem. 61, 219-240. (doi:10.1146/annurev.physchem. 012809.103457)
35. Wilson HR, Cowan JD. 1972 Excitatory and inhibitory interactions in localized populations of model neurons. Biophys. J. 12, 1-24. (doi:10.1016/S0006-3495(72)86068-5)
36. Mjolsness E, Sharp DH, Reinitz J. 1991 A connectionist model of development. J. Theor. Biol. 152, 429-453. (doi:10.1016/S0022-5193(05)80391-1)
37. Chen C, Baumann WT, Clarke R, Tyson JJ. 2013 Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. FEBS Lett. 587, 3327-3334. (doi:10.1016/j.febslet.2013.08.022)
38. Graham R, Tel T. 1986 Nonequilibrium potential for coexisting attractors. Phys. Rev. A 33, 1322-1337. (doi:10.1103/PhysRevA.33.1322)
39. Gupta PB, Fillmore CM, Jiang GZ, Shapira SD, Tao K, Kuperwasser C, Lander ES. 2011 Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644. (doi:10.1016/j.cell.2011.07.026)
40. Kussell E, Kishony R, Balaban NQ, Leibler S. 2005 Bacterial persistence: a model of survival in changing environments. Genetics 169, 1807-1814. (doi:10.1534/genetics.104.035352)
41. Weinan E, Ren WQ, Vanden-Eijnden E. 2004 Minimum action method for the study of rare events. Commun. Pur. Appl. Math. 57, 637-656. (doi:10.1002/cpa. 20005)
42. Freidlin M, Weber M. 2007 Random perturbations of dynamical systems and diffusion processes with conservation laws (vol. 137, pg 595, 2007). Probab. Theory Rel. 137, 595-596. (doi:10.1007/s00440-006-0027-0)
43. Wang J, Xu L, Wang E, Huang S. 2010 The potential landscape of genetic circuits imposes the arrow of time in stem cell differentiation. Biophys. J. 99, 29-39. (doi:10.1016/j.bpj.2010.03.058)
44. Greaves M, Maley CC. 2012 Clonal evolution in cancer. Nature 481, 306-313. (doi:10.1038/nature10762)
45. Toy W et al. 2013 ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445. (doi:10.1038/ng. 2822)
46. Robinson DR et al. 2013 Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451. (doi:10.1038/ng.2823)
47. Li S et al. 2013 Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116-1130. (doi:10.1016/j.celrep.2013.08.022)
48. Singh A, Settleman J. 2010 EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751. (doi:10.1038/onc.2010.215)
49. Tomaskovic-Crook E, Thompson EW, Thiery JP. 2009 Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 11, 213. (doi:10.1186/bcr2416)
50. Mackay A et al. 2011 Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J. Natl Cancer Inst. 103, 662-673. (doi:10.1093/jnci/djr071)
51. Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y, Weiner LM, Clarke R. 2011 Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat. Rev. Cancer 11, 523-532. (doi:10.1038/nrc3081)
52. Sha W, Moore J, Chen K, Lassaletta AD, Yi CS, Tyson JJ, Sible JC. 2003 Hysteresis drives cell-cycle transitions in Xenopus laevis egg extracts. Proc. Natl Acad. Sci. USA 100, 975-980. (doi:10.1073/pnas.0235349100)
53. Cui J, Chen C, Lu HZ, Sun TZ, Shen PP. 2008 Two independent positive feedbacks and bistability in the Bcl-2 apoptotic switch. PLoS ONE 3, e1469. (doi:10.1371/journal.pone.0001469)
54. Chen C, Cui J, Lu H, Wang R, Zhang S, Shen P. 2007 Modeling of the role of a Bax-activation switch in the mitochondrial apoptosis decision. Biophys. J. 92, 4304-4315. (doi:10.1529/biophysj.106.099606)
55. Clarke R et al. 2011 Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Horm. Mol. Biol. Clin. Invest. 5, 35-44. (doi:10.1515/HMBCI.2010.073)
56. Byrne HM. 2010 Dissecting cancer through mathematics: from the cell to the animal model. Nat. Rev. Cancer 10, 221-230. (doi:10.1038/nrc2808)
57. Komarova NL, Wodarz D. 2005 Drug resistance in cancer: principles of emergence and prevention. Proc. Natl Acad. Sci. USA 102, 9714-9719. (doi:10.1073/pnas.0501870102)
58. Merlo LMF, Pepper JW, Reid BJ, Maley CC. 2006 Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6, 924-935. (doi:10.1038/nrc2013)
59. Sottoriva A, Verhoeff JJ, Borovski T, McWeeney SK, Naumov L, Medema JP, Sloot PM, Vermeulen L. 2010 Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res. 70, 46-56. (doi:10.1158/0008-5472.CAN-09-3663)
60. Tomasetti C, Levy D. 2010 Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc. Natl Acad. Sci. USA 107, 16 766-16 771. (doi:10.1073/pnas.1007726107)
61. Labianca R et al. 2011 Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann. Oncol. 22, 1236-1242. (doi:10.1093/annonc/mdq580)
62. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. 2013 Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255. (doi:10.1038/nature11814)
63. Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC. 2010 Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Brit. J. Cancer 102, 495-499. (doi:10.1038/sj.bjc.6605514)